比克替拉韦/恩曲他滨/丙酚替诺福韦与多替拉韦+拉米夫定+富马酸替诺福韦二吡呋酯在中国HIV病毒学失败者中的比较:多中心开放标签随机对照非劣效试验研究方案
本研究为多中心、开放标签、随机对照非劣效试验,计划纳入374例在中国一线NNRTI方案治疗病毒学失败的HIV感染者,1:1随机接受BIC/FTC/TAF单片方案或DTG+3TC+TDF多片方案。主要终点为48周病毒抑制(HIV-1 RNA<50 copies/mL)比例,非劣效界值12%。
要点
- 比较BIC/FTC/TAF单片方案与DTG+3TC+TDF多片方案在病毒学失败者中的疗效与安全性。
- 主要终点为48周HIV-1 RNA<50 copies/mL的比例,非劣效界值12%。
- 旨在为耐药检测不可及的资源有限地区提供优化二线治疗的高质量证据。
核心结论
- 该试验旨在比较BIC/FTC/TAF单片方案与DTG+3TC+TDF多片方案在病毒学失败HIV感染者中的疗效、安全性和耐受性。
研究设计与样本
- 多中心、开放标签、随机对照非劣效试验,计划从中国14家诊所纳入374例一线NNRTI方案治疗病毒学失败的HIV感染者。
- 参与者按1:1随机接受每日一次BIC/FTC/TAF单片方案或每日一次DTG+3TC+TDF多片方案。
关键数值与推荐
- 主要终点为48周病毒抑制(HIV-1 RNA<50 copies/mL)的比例。
- 非劣效界值定义为12%。
- 次要终点包括病毒抑制时间、耐药相关突变出现、免疫学标志物、治疗依从性、患者报告结局和安全性特征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In China, non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens remain widely utilized as first-line antiretroviral therapy (ART) despite issues of low resistance barriers and significant side effects, leading to frequent treatment interruptions and virologic failures. Timely drug-resistance testing is often inaccessible, complicating subsequent treatment management. This trial aims to fill this critical gap by comparing the efficacy, safety, and tolerability of the single-tablet regimen (STR) of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) with the multi-tablet regimen (MTR) of dolutegravir plus lamivudine plus tenofovir disoproxil fumarate (DTG+3TC+TDF) in people living with HIV (PLWH) experiencing virologic failure. METHODS: This multicenter, open-label, randomized controlled non-inferiority trial will enroll 374 PLWH experiencing virologic failure of first-line NNRTI-based therapy from 14 clinics across China. Participants will be randomized 1:1 to receive either a once-daily STR of BIC/FTC/TAF or a once-daily MTR of DTG+3TC+TDF. The primary endpoint is the proportion achieving viral suppression (HIV-1 RNA < 50 copies/mL) at week 48. Secondary endpoints include the time to viral suppression, emergence of resistance-associated mutations (RAMs), immunologic markers, treatment adherence, patient-reported outcomes, and safety profiles. Data will be analyzed using intention-to-treat (ITT) and per-protocol (PP) populations, with non-inferiority defined using a margin of 12%. DISCUSSION: This trial aims to provide high-quality evidence for a simplified, high-barrier, STR as an optimized second-line strategy in resource-limited settings where drug resistance testing is inaccessible. TRIAL REGISTRATION: Chinese Clinical Trial Registry (Trial ID: ChiCTR2500108287). Registered on 27 August 2025. Retrospectively registered. https://www.chictr.org.cn .
引用
- Wang R, Ren Y, Li R, et al. Bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir plus lamivudine plus tenofovir disoproxil fumarate in people living with HIV experiencing virologic failure in China: a study protocol for a multicenter, open-label, randomized controlled non-inferiority trial. Trials. 2026. PMID: 42067921. doi:10.1186/s13063-026-09749-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。